Occurrence of Residual Cancer Within Re-excisions After Subcutaneous Mastectomy of Invasive Breast Cancer and Ductal Carcinoma
Subcutaneous mastectomy
re-excisions
residual cancer
Journal
In vivo (Athens, Greece)
ISSN: 1791-7549
Titre abrégé: In Vivo
Pays: Greece
ID NLM: 8806809
Informations de publication
Date de publication:
Historique:
received:
08
04
2020
revised:
17
04
2020
accepted:
18
04
2020
entrez:
2
7
2020
pubmed:
2
7
2020
medline:
22
6
2021
Statut:
ppublish
Résumé
Surgical margin status remains an important determinant for recurrence of invasive breast cancer and ductal carcinoma in situ. We compared the number of positive margins in initial histology with rates of residual tumor in re-excision specimens. Furthermore, we analysed cost-effectiveness of re-excisions. 101 patients treated with secondary surgery were included. The first group underwent breast conserving surgery and secondary mastectomy. The second group was primarily treated with subcutaneous mastectomy followed by secondary surgery. Within the first group, 22.7% did not show residual tumor in the re-excision specimen. Of the second group, 54.3% had no residual tumor. Consequentially 45.7% needed a re-excision to achieve R0 status. Cost-effectiveness was determined as secondary endpoint. If a patient needs a secondary mastectomy the hospital gains 602,65€ in comparison to a primary breast conserving operation. In every second patient who had first received a subcutaneous mastectomy, no tumor could be detected in the secondary operation despite a previous R1 status.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
Surgical margin status remains an important determinant for recurrence of invasive breast cancer and ductal carcinoma in situ. We compared the number of positive margins in initial histology with rates of residual tumor in re-excision specimens. Furthermore, we analysed cost-effectiveness of re-excisions.
PATIENTS AND METHODS
METHODS
101 patients treated with secondary surgery were included. The first group underwent breast conserving surgery and secondary mastectomy. The second group was primarily treated with subcutaneous mastectomy followed by secondary surgery.
RESULTS
RESULTS
Within the first group, 22.7% did not show residual tumor in the re-excision specimen. Of the second group, 54.3% had no residual tumor. Consequentially 45.7% needed a re-excision to achieve R0 status. Cost-effectiveness was determined as secondary endpoint. If a patient needs a secondary mastectomy the hospital gains 602,65€ in comparison to a primary breast conserving operation.
CONCLUSION
CONCLUSIONS
In every second patient who had first received a subcutaneous mastectomy, no tumor could be detected in the secondary operation despite a previous R1 status.
Identifiants
pubmed: 32606175
pii: 34/4/2015
doi: 10.21873/invivo.12000
pmc: PMC7439870
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2015-2019Informations de copyright
Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Références
Pathologica. 2019 Mar;111(1):31-36
pubmed: 31217620
Ann Surg Oncol. 2004 Oct;11(10):915-20
pubmed: 15383425
Breast. 2014 Dec;23(6):870-5
pubmed: 25305040
Ann Surg Oncol. 2018 Jul;25(7):1936-1942
pubmed: 29748884
Eur J Surg Oncol. 2018 Nov;44(11):1725-1735
pubmed: 30120037
Eur J Cancer. 2010 Dec;46(18):3219-32
pubmed: 20817513
Am Surg. 2010 Mar;76(3):331-4
pubmed: 20349668
Int J Radiat Oncol Biol Phys. 1999 Jul 15;44(5):1005-15
pubmed: 10421533
Invest Radiol. 2015 Sep;50(9):615-28
pubmed: 26083829
Breast Cancer Res Treat. 2009 Jul;116(1):171-7
pubmed: 18815880
Mod Pathol. 2004 Jan;17(1):81-8
pubmed: 14657957
Ann Surg Oncol. 2008 Sep;15(9):2542-9
pubmed: 18618180
Breast J. 2012 Jul-Aug;18(4):339-44
pubmed: 22616572
J Surg Oncol. 2016 Mar;113(3):256-63
pubmed: 26394558